Provided by Tiger Fintech (Singapore) Pte. Ltd.

Syros Pharmaceuticals

0.0924
+0.015920.78%
Post-market: 0.0820-0.0104-11.26%19:59 EDT
Volume:81.32M
Turnover:8.90M
Market Cap:2.48M
PE:-0.03
High:0.1275
Open:0.0800
Low:0.0765
Close:0.0765
Loading ...

Company Profile

Company Name:
Syros Pharmaceuticals
Exchange:
NASDAQ
Establishment Date:
2011
Employees:
68
Office Location:
35 CambridgePark Drive,4th Floor,Cambridge,Massachusetts,United States
Zip Code:
02140
Fax:
- -
Introduction:
Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors. It has target discovery, research collaboration, and option agreement with Incyte Corporation to identify therapeutic targets with a focus on myeloproliferative neoplasms; and a license agreement with TMRC Co. Ltd. for the development and commercialization of tamibarotene. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was incorporated in 2011 and is headquartered in Cambridge, Massachusetts.

Directors

Name
Position
Nancy Simonian
President,Chief Executive Officer and Director
Peter Wirth
Chairman
Amir Nashat
Director
Marsha H. Fanucci
Director
Phillip A. Sharp
Director
Richard A. Young
Director
Robert T. Nelsen
Director
Sanj K. Patel
Director
Srinivas Akkaraju
Director
Vicki L. Sato
Director

Shareholders

Name
Position
Nancy Simonian
President,Chief Executive Officer and Director
Joseph J. Ferra, Jr.
Chief Financial Officer
David A. Roth
Chief Medical Officer
Eric R. Olson
Chief Scientific Officer
Gerald E. Quirk
Chief Legal and Administrative Officer
Jeremy P. Springhorn
Chief Business Officer